1 day-0.96%
1 week-4.94%
Current month-3.75%
1 month+10.79%
3 months+106.43%
6 months+119.37%
1 week 150
Extreme 150
165.5
1 month 134
Extreme 134
185
Current year 37.55
Extreme 37.55
185
1 year 37.55
Extreme 37.55
185
3 years 37.55
Extreme 37.55
185
5 years 37.55
Extreme 37.55
185
10 years 37.55
Extreme 37.55
185
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 13/01/2017
Chief Executive Officer - 13/01/2017
Director of Finance/CFO - 23/09/2019
Director TitleAgeSince
Director/Board Member 52 25/07/2019
Chairman - 13/01/2017
Director/Board Member - 23/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-4.94% - - 65Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
+0.56%-2.75%+20.83%+80.09% 5.74TCr
+0.67%-2.67%+2.05%+35.41% 4.76TCr
+0.36%+0.81%+342.39%+748.97% 4.43TCr
-0.96%-4.50%+24.96%+31.45% 4.25TCr
-0.20%-0.77%+4.13%+111.69% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.28%+3.56%+31.67%+28.90% 2.85TCr
+0.05%-1.64%-8.14%-12.10% 2.43TCr
Average +0.47%-1.02%+52.95%+130.30% 3.91TCr
Weighted average by Cap. +0.95%-0.85%+57.21%+139.62%

Financials

2024 2025
Net sales 8L 25.21T 22.4T 20.9T 19.05T 35.93T 24.23L 36.27T 3L 98.03T 12.39L 94.64T 92.59T 39.76L 5.03Cr 15.79L 14.03L 13.09L 11.93L 22.5L 15Cr 22.71L 1.58Cr 61.39L 7.76Cr 59.27L 57.98L 25Cr
Net income -44Cr -1.38Cr -1.23Cr -1.15Cr -1.04Cr -1.97Cr -132.88Cr -1.99Cr -14Cr -5.38Cr -68Cr -5.19Cr -5.08Cr -218.01Cr -110.65Cr -3.47Cr -3.09Cr -2.88Cr -2.63Cr -4.95Cr -333.92Cr -5Cr -35Cr -14Cr -170.71Cr -13Cr -13Cr -547.86Cr
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
02/26/02 NT$154.00 -0.96% 6,86,154
01/26/01 NT$155.50 -2.81% 11,18,307
30/26/30 NT$160.00 -0.93% 7,86,671
  1. Stock Market
  2. Stocks
  3. 7871 Stock